Literature DB >> 2267133

Oncogenes in multiple myeloma: point mutation of N-ras.

R L Paquette1, J Berenson, A Lichtenstein, F McCormick, H P Koeffler.   

Abstract

Alterations of ras, c-myc and bcl-1 have been described in hematologic malignancies of lymphoid origin. We investigated the structure of these genes and evaluated the frequency of point mutations involving H-, K- or N-ras in bone marrow samples from patients with multiple myeloma. No abnormalities were detected in the c-myc and bcl-1 genes, but two of 17 patients were found to have N-ras mutations by differential oligonucleotide hybridization and dideoxynucleotide sequencing following amplification by polymerase chain reaction. Bone marrow DNA from both patients had identical missense mutations of N-ras codon 61 changing CAA to AAA, resulting in a substitution of lysine for glutamine in the encoded protein. Multiple myeloma is the first mature B cell neoplasm found to harbor ras mutations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267133

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Proto-oncogene analysis in multiple myeloma.

Authors:  M Ladanyi; S Wang; R Niesvizky; H Feiner; J Michaeli
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

2.  MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.

Authors:  Y Shi; P Frost; B Hoang; Y Yang; R Fukunaga; J Gera; A Lichtenstein
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 3.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.

Authors:  C L Rosenberg; E Wong; E M Petty; A E Bale; Y Tsujimoto; N L Harris; A Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

7.  Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

Authors:  Bao Hoang; Li Zhu; Yijiang Shi; Patrick Frost; Huajun Yan; Sanjai Sharma; Sherven Sharma; Lee Goodglick; Steven Dubinett; Alan Lichtenstein
Journal:  Blood       Date:  2006-02-23       Impact factor: 22.113

8.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.